Preview

Malignant tumours

Advanced search

Association of XRCC1, HMMR genes with breast cancer in the Kyrgyz ethnic group

https://doi.org/10.18027/2224-5057-2018-8-4-45-49

Abstract

An association of genes XRCC1 and HMMR with breast cancer (BC) has never been tested in the Kyrgyz ethnic group. This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 53 years (24–74, SE mean = 0.967, STD=9.81). The extraction of DNA was carried out from venous blood. The genotyping was conducted by using the method of polymerase chain reaction and restriction fragment length polymorphism. When comparing the results of genotyping, the histological structure of the tumor and the «menopause» factor, Fisher»s exact test was used. Calculation of the odds ratio was carried out by cross tabulation method. A statistically significant link between the XRCC1 Arg194Trp polymorphism and the menopausal status was observed (p=0,018). The Arg / Arg genotype of XRCC1 Arg194Trp polymorphism occurred in 52 % of cases in women at menopausal age, whereas in women before the onset of menopause, the genotype Arg / Arg occurred in 78.8 % of BC cases (p=0.009). The CT genotype of HMMR V353A polymorphism was identified as “protective” factor – OR=0.481, 95 % CI [0.27‑0.85]. There was no statistically significant association between the results of genotyping and histological structure of the tumor, as well as the age of verification of the diagnosis of BC.

About the Authors

A. Semetei kyzy
Kyrgyz Russian Slavic University, Bishkek
Kyrgyzstan
MD, Researcher of the Oncology and Radiotherapy Department


E. K. Makimbetov
Kyrgyz Russian Slavic University, Bishkek
Kyrgyzstan
MD, DSc Med, Professor, Oncology and Radiotherapy Department


J. T. Isakova
Research Institute of Molecular Biology and Medicine, Bishkek
Kyrgyzstan
MD, DSc Med, Senior Researcher


I. O. Kudaibergenova
Kyrgyz State Medical Academy, Bishkek
Kyrgyzstan
MD, DSc Med, Professor, Oncology Department


Z. P. Kamarli
Kyrgyz Russian Slavic University , Bishkek
Kyrgyzstan
MD, DSc Med, Professor, Head of the Oncology and Radiotherapy Department


References

1. Sieber O. M., Heinimann K., Tomlinson I. P. Genomic instability – the engine of tumorigenesis? Nat. Rev. Cancer. 2003. Vol. 3. P. 701–708.

2. Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N. Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Res. 2013. Vol. 73 (5). P. 1621–1634. DOI: 10.1158 / 0008‑5472.CAN-12‑2929 2013.

3. Ladiges W. C. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006. Vol. 25. P. 1612–1619.

4. Horton J. K., Watson M., Stefanick D. F., Shaughnessy D. T., Taylor J. A., Wilson S. H. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008. Vol. 18. P. 48–63.

5. Zhang R., Niu Y., Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol. Lett. 2010. Vol. 192. P. 108–114.

6. Tischkowitz M., Xia B., Sabbaghian N. et al. Analysis of PALB2 / FANCN-associated breast cancer families. Proc. Natl. Acad. Sci. USA. 2007. Vol. 104. P. 6788–6793.

7. Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T. et al. PALB2, which encodes a BRCA2‑interacting protein, is a breast cancer susceptibility gene. Cancer. 2007. Vol. 39. P. 165–167.

8. Akent’eva N. P., Shushanov S. S., Kotelnikov A. I. Effects of RHAAM / HMMR – selective peptides on survival of breast cancer cells. Bulletin of Experimental Biology and Medicine. 2015. Vol. 159. No. 5. P. 658–661.

9. Lejeune F. J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 1998. Vol. 10. P. 573–580.

10. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001. Vol. 357. P. 539–545

11. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Res. 2002. Vol. 13. P. 135–141.

12. Leek R. D., Landers R., Fox S. B., Ng F., Harris A. L. et al. (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Brit. J. Cancer. 1998. Vol. 77. P. 2246–2251.


Review

For citations:


Semetei kyzy A., Makimbetov E.K., Isakova J.T., Kudaibergenova I.O., Kamarli Z.P. Association of XRCC1, HMMR genes with breast cancer in the Kyrgyz ethnic group. Malignant tumours. 2018;8(4):45-49. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-4-45-49

Views: 958


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)